Hong I. Wan

Hong I. Wan has extensive experience in the biopharmaceutical industry. Currently, they are serving as the President, Chief Executive Officer, and Co-Founder of Tallac Therapeutics, where they lead the development of immunotherapy candidates using the company's TRAAC platform. Prior to this, Wan held several roles at ALX Oncology, including Consulting CSO and Chief Scientific Officer, where they contributed to the development of ALX148, a CD47 blocking therapeutic. Hong I. also served as the VP of Early Development and Translational Medicine at Alexo Therapeutics. Before ALX Oncology, Wan worked at Pfizer as a Senior Director in Biotechnology Clinical Development and as a Director in Translational and Molecular Medicine. Their earlier experience includes positions at Wyeth as a Director and Associate Director in Clinical Translational Medicine, and at Renovis as a Project Leader and Senior Scientist.

Hong I. Wan holds a PhD in Molecular and Cell Biology from the University of California, Berkeley. Prior to that, they obtained an AB in Biochemical Sciences from Harvard University. Hong I. Wan also studied Biochemistry at Peking University, although the specific degree they earned is not specified.